Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 4Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Ovarian Neoplasms 40Breast Neoplasms 14Uterine Cervical Neoplasms 13Melanoma 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 8Head and Neck Neoplasms 8Stomach Neoplasms 7Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Esophageal Neoplasms 6Anus Neoplasms 6Vaginal Neoplasms 5Penile Neoplasms 5Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Carcinoma, Hepatocellular 5Vulvar Neoplasms 4Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma, Synovial 4Oropharyngeal Neoplasms 4Neoplasms 4Multiple Myeloma 4Mesothelioma 4Carcinoma, Renal Cell 4Recurrence 3

Interventions

pembrolizumab 2fludarabine 2SS1(dsFv)PE38 2Platinum 2Hyperthermic Intraperitoneal Chemotherapy 2Cyclophosphamide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sodium thiosulfate 1enzalutamide 1entinostat 1X-Rays 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Referral and Consultation 1Polymerase Chain Reaction 1Paclitaxel 1Nivolumab 1Microarray Analysis 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × fludarabine × Gynecologic × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡